PMID- 21651446
OWN - NLM
STAT- MEDLINE
DCOM- 20110928
LR  - 20181201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 10
DP  - 2011 Jul
TI  - Pioglitazone: a valuable component of combination therapy for type 2 diabetes 
      mellitus.
PG  - 1457-61
LID - 10.1517/14656566.2011.568477 [doi]
AB  - Several classes of drugs have been developed to treat type 2 diabetes mellitus 
      (T2DM). Pioglitazone is now the only thiazolidinedione approved for the treatment 
      of T2DM and can be administered in combination with metformin, sulfonylureas, 
      exenatide, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin. It improves 
      glycemic control with an extremely low incidence of hypoglycemia. In addition to 
      reducing insulin resistance, it may also improve pancreatic beta-cell secretory 
      function. Moreover, it exhibits a variety of favorable pleiotropic effects. The 
      latter include anti-inflammatory, antioxidant, vasoprotective, antihypertensive 
      and hypolipidemic actions. Finally, this agent has been shown to improve 
      experimental diabetic neuropathy and alleviate neuropathic pain, as well as 
      decreasing urinary albumin excretion in patients with diabetes. Thus, 
      pioglitazone emerges as a valuable hypoglycemic agent for combination therapy in 
      T2DM. Importantly, however, patients should be appropriately selected, especially 
      to avoid those with heart failure, in order to minimize adverse events 
      attributable to water retention.
CI  - (c) 2011 Informa UK, Ltd.
FAU - Papanas, Nikolaos
AU  - Papanas N
FAU - Katsiki, Niki
AU  - Katsiki N
FAU - Hatzitolios, Apostolos I
AU  - Hatzitolios AI
FAU - Maltezos, Efstratios
AU  - Maltezos E
LA  - eng
PT  - Comment
PT  - Editorial
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CON - Expert Opin Pharmacother. 2011 Jul;12(10):1571-84. PMID: 21639813
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*pharmacology
MH  - Insulin Resistance
MH  - Pioglitazone
MH  - Thiazolidinediones/administration & dosage/adverse effects/*pharmacology
EDAT- 2011/06/10 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/06/10 06:00
PHST- 2011/06/10 06:00 [entrez]
PHST- 2011/06/10 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 10.1517/14656566.2011.568477 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Jul;12(10):1457-61. doi: 
      10.1517/14656566.2011.568477.